Walvax Biotechnology Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	6.7yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Apr 07

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Apr 02

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Mar 01

CEO

Walvax Biotechnology has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Runsheng Jiang	Director & President	no data	CN¥2.90m	0.058% CN¥ 13.7m
Hua Zhou	Chief Financial Officer	9.9yrs	CN¥2.23m	0.048% CN¥ 11.2m
Jiankang Zhang	VP & Director	no data	CN¥2.64m	no data
Yun Yan Wu	Director of Operations	6.6yrs	no data	no data
Jin Long Zhao	Chief Investment Officer	6.6yrs	no data	no data
Lin Yuan	Technical Director	6.8yrs	no data	no data
Wei Yao	Marketing Director	7.8yrs	no data	no data
Shao Zhong Dong	VP & Director	no data	no data	no data
Yu Ran Liu	Board Secretary	1.6yrs	no data	no data

6.7yrs

Average Tenure

51yo

Average Age

Experienced Management: 300142's management team is seasoned and experienced (6.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Runsheng Jiang	Director & President	7.9yrs	CN¥2.90m	0.058% CN¥ 13.7m
Jiankang Zhang	VP & Director	4yrs	CN¥2.64m	no data
Shao Zhong Dong	VP & Director	2.3yrs	no data	no data
Yunchun Li	Chairman	14.9yrs	CN¥4.03m	1.7% CN¥ 399.4m
Zhen Huang	Vice Chairman	7yrs	CN¥4.04m	1.11% CN¥ 260.3m
Jianmei Zhao	Independent Director	3.8yrs	CN¥102.00k	no data
Shiqing Ding	Chairwoman of the Supervisory Board	3.8yrs	no data	no data
Yongwu Fan	Non-Independent Director	3.8yrs	no data	no data
Ting Yan	Director	2.5yrs	CN¥201.80k	0.0044% CN¥ 1.0m
Jinyu Zhu	Independent Director	1.6yrs	CN¥21.20k	no data
Ganghong Sun	Independent Director	1.6yrs	CN¥21.20k	no data
Lingbing Zeng	Independent Director	1.6yrs	CN¥21.20k	no data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Board: 300142's board of directors are considered experienced (3.8 years average tenure).

Walvax Biotechnology Management

Management criteria checks 2/4

Key information

Recent management updates

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Less than half of directors are independent

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings

Consensus revenue estimates decrease by 11%

Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 11% to CN¥21.00

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 19, 2024

Full year 2023 earnings: EPS misses analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Is Walvax Biotechnology (SZSE:300142) A Risky Investment?

Consensus revenue estimates fall by 12%

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Price target decreased by 9.8% to CN¥23.00

Consensus revenue estimates fall by 18%

Less than half of directors are independent

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Price target decreased by 25% to CN¥25.50

Consensus revenue estimates fall by 21%

Price target decreased by 8.1% to CN¥34.00

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 11, 2023

Price target increased by 19% to CN¥37.00

Price target decreased by 9.1% to CN¥30.00

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 16%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Walvax Biotechnology Co., Ltd. Announces Executive Appointments

Price target decreased to CN¥32.00

Second quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.18 in 2Q 2021)

Walvax Biotechnology Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CN¥36.00

Walvax Biotechnology Co., Ltd. Approves Cash Dividend for 2021

Consensus forecasts updated

Walvax Biotechnology Co., Ltd., Annual General Meeting, Apr 12, 2022

Third quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.24 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.18 (vs CN¥0.052 in 2Q 2020)

Walvax Biotechnology Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 19, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.012 loss in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.65 (vs CN¥0.092 in FY 2019)

Walvax Biotechnology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥48.62

New 90-day low: CN¥36.53

New 90-day low: CN¥48.42

New 90-day low: CN¥48.82

Third quarter earnings released

Walvax Biotechnology Co., Ltd. to Report Q3, 2020 Results on Oct 21, 2020

Earnings released

New 90-day high - CN¥71.98

Walvax Biotechnology Co., Ltd. to Report First Half, 2020 Results on Aug 15, 2020

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age